The biopharmaceutical oncology company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker Symbol: T9G) has reported several successes this year. At the end of March 2024, the company received approval from the Japanese Patent Office for its drug candidate VDA-1275. This compound is being used in the preclinical phase against cancer cells and has already demonstrated notable success. The main molecule in VDA-1275 was able to show its effectiveness in animal trials with a variety of tumors. When VDA-1275 was used in combination with two widely-used chemotherapeutic agents, strong synergy effects were observed in lab tests on cultured human liver cells.
News & Events